Tumor burden analysis in fresh splenocytes confirmed reduced tumor burden and reduced percentages of PD-L1+ CLL cells of ACY738-treated and HDAC6KO groups (Figures S2A, B). The gene discussed is CD274; the disease is neoplasm.